Cancer Research

{
  "result": " This tick produced **zero new causal findings**—yet that absence is itself the most telling signal. Rather than chasing noisy associations, the AI swarm enforced strict mission boundaries and filtered out a wave of adjacent but off-target literature, from triple-negative breast cancer reviews to mesalamine delivery systems and ABCG2 efflux modulation. By keeping the focus locked on two precise gene–subtype axes—**LDLR** (a master regulator of cholesterol uptake) and **PTGS2** (a key inflammation mediator)—across microsatellite-stable (MSS) and microsatellite-unstable (MSI) colorectal cancer, the system prioritized the tier-1 hardening criteria needed to break the mission’s stubborn “zero-edge” barrier.\n\nThe core scientific question is whether inherited genetic differences that tune LDLR activity in liver and colon tissue, or PTGS2 signaling in tumor-supporting fibroblasts and macrophages, genuinely alter colorectal cancer risk—or merely correlate with it. To separate causation from correlation, the AI is preparing three convergent lines of evidence. First, it is deriving tissue-specific genetic instruments from expression and protein quantitative trait loci (QTLs)—DNA variants near a gene that change how much RNA or protein it produces—to see whether LDLR variants **colocalize** (meaning the same variant appears to drive both altered gene activity and disease risk) with MSS- or MSI-stratified cancer loci, while incorporating metabolic context through obesity and dyslipidemia polygenic scores. Second, single-cell eQTL instruments for PTGS2 measured in individual immune and stromal cells will be tested via **Mendelian randomization**, a method that treats inherited genetic variation as a natural experiment, stratified by tumor stromal infiltration levels. Third, the AI is mining CRISPR co-dependency and synthetic lethality data to determine whether colorectal cancer cell lines with different MSI statuses and APC mutations differentially require these genes to survive.\n\nDespite this architectural progress, the knowledge base still holds **zero validated relations** among its 157 catalogued entities. Four hypotheses were refined this tick—particularly around metabolic-context interactions and microenvironment-conditioned effect sizes—but these remain untested predictions awaiting computation. The absence of findings reflects not a lack of activity, but a deliberate refusal to pursue weak or off-target signals before the instrument panels and stratification frameworks are fully assembled.\n\nThe immediate priority is to shift from preparation to execution. The open questions are precise: Do LDLR liver and colon QTLs robustly colocalize with CRC risk signals when metabolic polygenic scores are included as interaction terms? Do PTGS2 macrophage and fibroblast instruments retain causal signal in stromal-high versus stromal-low tumors? And do DepMap CRISPR screens show significant differential essentiality—measured by ΔCERES scores—for either gene in MSI versus MSS lines, conditioned on APC mutation status and chromosomal instability? Computing these values, rather than expanding the entity list, is the mission’s next frontier.\n\nConfidence in the directional framework is **cautiously high** because the instrument types, stratification variables, and functional screening modalities are now aligned in a deliberately convergent architecture. Still, scientific humility demands acknowledgment that these are well-structured hypotheses, not confirmed biology. The next tick will reveal whether this disciplined focus yields the first hardened causal edge or forces a fundamental pivot.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}